Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Metastatic Breast Cancer
Clinical trial register · United States · industry-sponsored

Metastatic Breast Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 12 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
Florida 24 California 20 Arizona 16 Illinois 14 Texas 13
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Olema Pharmaceuticals, Inc.4 AstraZeneca2 BeOne Medicines2 Stemline Therapeutics, Inc.2 Eli Lilly and Company2
State
Florida24 California20 Arizona16 Illinois14 Texas13
All 35 states
Target enrolment
to

Metastatic Breast Cancer trials in the USA

33 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Janssen Research & Development, LLC
Phase 1
170
Connecticut, Florida, Massachusetts, Tennessee, Texas, Virginia
2026-04-09
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-11-03
Active, closed
Boehringer Ingelheim
Observational
7,933
Connecticut
2025-09-30
Recruiting
BioNTech SE
Phase 1/2
380
California, Florida, Georgia, Illinois, Michigan, Missouri, New Jersey, New York
2025-04-23
Recruiting
BeOne Medicines
Phase 1
120
Iowa, Texas, Washington
2025-02-04
Recruiting
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
DrugsPalazestrant·Fulvestrant
Olema Pharmaceuticals, Inc.
Phase 1
180
Arizona, Colorado, Florida, Louisiana, Massachusetts, Michigan, New York, Ohio
2024-12-16
Active, closed
Merck Sharp & Dohme LLC
Phase 2
120
Arizona, California, Georgia, Louisiana, Nevada, New Jersey, Texas, Wisconsin
2024-11-27
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
DrugAlisertib
Puma Biotechnology, Inc.
Phase 2
225
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-11-19
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
California, Florida, Indiana, Massachusetts, Missouri, New York, Tennessee, Texas
2024-10-29
Recruiting
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
DrugRYZ101
RayzeBio, Inc.
Phase 1/2
64
Arizona, California, Colorado, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-07-19
Recruiting
Boehringer Ingelheim
Phase 1/2
768
California, Connecticut, Florida, Illinois, Indiana, Iowa, Massachusetts, Michigan
2024-06-28
Active, closed
DualityBio Inc.
Phase 3
541
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas
2024-01-18
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic
DrugsRetifanlimab·Cyclophosphamide
BriaCell Therapeutics Corporation
Phase 3
404
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2023-12-05
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2023-12-01
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2023-11-16
Recruiting
LeonaBio
Phase 3
600
Arizona, California, Florida, Georgia, Kentucky, Maryland, Massachusetts, Michigan
2023-10-31
Recruiting
Hoffmann-La Roche
Phase 3
230
Arizona, California, District of Columbia, Maryland, Massachusetts, Michigan, Nevada, New Jersey
2023-09-08
Active, closed
Stemline Therapeutics, Inc.
Phase 2
61
Arkansas, Illinois, Nevada, Texas
2023-05-19
Active, closed
Stemline Therapeutics, Inc.
Phase 1/2
435
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-01-24
Recruiting
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
DrugsElacestrant·Exemestane·Everolimus·Abemaciclib
Ellipses Pharma
Phase 1/2
95
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas, Virginia
2023-01-11
Active, closed
Menarini Silicon Biosystems, INC
Observational
65
Minnesota, Wisconsin
2022-12-12
Active, closed
Olema Pharmaceuticals, Inc.
Phase 1
190
Arizona, California, Colorado, Florida, Iowa, Massachusetts, Michigan, Minnesota
2022-08-31
Recruiting
SynDevRx, Inc.
Phase 1/2
52
California, Florida, Illinois, Michigan, Ohio, Pennsylvania, Tennessee, Texas
2022-08-26
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2022-07-07
Recruiting
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
NCT04872166Advanced Solid Tumor, Metastatic Breast Cancer
DrugBTX-A51
Edgewood Oncology Inc.
Phase 1
112
Florida, Ohio, Tennessee, Texas
2021-06-07
Active, closed
AstraZeneca
Phase 1/2
245
Florida, New York, Ohio, Tennessee, Texas, Virginia
2020-12-28
Active, closed
AstraZeneca
Phase 1
138
New York, North Carolina, Tennessee, Texas
2020-12-17
Recruiting
Minerva Biotechnologies Corporation
Phase 1
69
California
2020-01-15
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Arizona, Arkansas, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2019-12-10
Active, closed
Phoenix Molecular Designs
Phase 1/2
61
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Ohio, Texas
2019-11-14
Recruiting
Hoffmann-La Roche
Phase 1/2
1,132
California, Colorado, Florida, Illinois, Minnesota, Nebraska, Nevada, New Jersey
2018-03-30
Active, closed
Eli Lilly and Company
Phase 2
234
Arizona, New Hampshire, Tennessee, Texas, Wisconsin
2016-09-14
Active, closed
PhII ICb With/Without Erbitux in MBC Pts
NCT00248287Metastatic Breast Cancer
DrugsErbitux·Irinotecan·Carboplatin
US Oncology Research
Phase 2
154
Alabama, Arizona, Colorado, Connecticut, Florida, Illinois, Indiana, Kansas
2005-07-28
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/metastatic-breast-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 12 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies listing the condition Metastatic Breast Cancer.

How many Metastatic Breast Cancer trials are recruiting in the US?

18 of the 33 studies on this page are recruiting new participants as of the 12 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Metastatic Breast Cancer), 33 studies
PhaseStudiesRecruitingShare
Phase 110730.3%
Phase 1/29627.3%
Phase 36418.2%
Phase 25115.2%
Observational206.1%
Phase 4103%

Most active sponsors

Lead sponsors with the most studies (Metastatic Breast Cancer)
Lead sponsorStudiesRecruiting
Olema Pharmaceuticals, Inc.42
AstraZeneca20
BeOne Medicines22
Boehringer Ingelheim21
Eli Lilly and Company20
Hoffmann-La Roche22
Stemline Therapeutics, Inc.20
BioNTech SE11
BriaCell Therapeutics Corporation11
DualityBio Inc.10

Top states

Top states (Metastatic Breast Cancer), by number of studies with a site there
StateStudies
Florida24
California20
Arizona16
Illinois14
Texas13
Colorado12
Georgia11
Massachusetts11
Michigan11
Connecticut9
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.